首页> 外文期刊>Radiation Oncology Journal >Short-course versus long-course neoadjuvant chemoradiotherapy in patients with rectal cancer: preliminary results of a randomized controlled trial
【24h】

Short-course versus long-course neoadjuvant chemoradiotherapy in patients with rectal cancer: preliminary results of a randomized controlled trial

机译:直肠癌患者的短期课程与长期Neoadjuvant ChemorAdoothia治疗:随机对照试验的初步结果

获取原文
           

摘要

Purpose Colorectal cancer is becoming an increasing concern in the middle-aged population of Iran. This study aimed to compare the preliminary results of short-course and long-course neoadjuvant chemoradiotherapy treatment for rectal cancer patients. Materials and Methods In this clinical trial we recruited patients with rectal adenocarcinoma located from 5 cm to 15 cm above the anal verge. Patients in group I (short-course) received three-dimensional conformational radiotherapy with a dose of 25 Gy/5 fractions in 1 week plus concurrent XELOX regimen (capecitabine 625 mg/msup2/sup from day 1–5 twice daily and oxaliplatin 50 mg/msup2/sup on day 1 once daily). Patients in group II (long-course) received a total dose of 50–50.4 Gy/25–28 fractions for 5 to 5.5 weeks plus capecitabine 825 mg/msup2/sup twice daily. Both groups underwent consolidation chemotherapy followed by delayed surgery at least 8 weeks after radiotherapy completion. The pathological response was assessed with tumor regression grade. Results In this preliminary report on complications and pathological response, 66 patients were randomized into two study groups. Mean duration of radiotherapy in groups I and II was 5 ± 1 days (range, 5 to 8 days) and 38 ± 6 days (range, 30 to 58 days). The median follow-up was 18 months. Pathological complete response was achieved in 32.3% and 23.1% of patients in the short-course and long-course groups, respectively (p = 0.558). Overall, acute grade 3 or higher treatment-related toxicities occurred in 24.2% and 22.2% of patients in group I and II, respectively (p = 0.551). No acute grade 4 or 5 adverse events were observed in either group except one grade 4 hematologic toxicity that was seen in group II. Within one month of surgery, no significant difference was seen regarding grade ≥3 postoperative complications (p = 0.333). Conclusion For patients with rectal cancer located at least 5 cm above the anal verge, short-course radiotherapy with concurrent and consolidation chemotherapy and delayed surgery is not different in terms of acute toxicity, postoperative morbidity, complete resection, and pathological response compared to long-course chemoradiotherapy.
机译:目的结直肠癌正在成为伊朗中年人口的日益问题。本研究旨在比较直肠癌患者的短程和长期疗程的初步结果和长期内轴的化学疗法治疗。该临床试验中的材料和方法我们招募了位于肛门边缘5厘米至15厘米的直肠腺癌患者。 I族(短期课程)患者在1周内接受了三维构象放疗,用剂量为25 Gy / 5分数,加同日Xelox方案(Capecitabine 625mg / m 2 在第1-5天每日两次和Oxaliplatin 50 mg / m 2 每日一次)。 II组患者(长期)(长期)接受了50-50.4 Gy / 25-28分数的总剂量,5至5.5周加上Capecitabine 825mg / m 2 / sup>每日两次。两组均在放疗完成后至少8周后,两组均接受了延迟手术。通过肿瘤回归等级评估病理反应。导致对并发症和病理反应的初步报告,66名患者随机分为两组研究组。 I和II基团的放射疗法的平均持续时间为5±1天(范围,5至8天)和38±6天(范围,30至58天)。中位后续时间为18个月。在短期和长期组的32.3%和23.1%的患者中达到了病理完全反应(P = 0.558)。总体而言,急性级别3或更高的治疗相关毒性分别发生24.2%和22.2%的患者(P = 0.551)。在任一组中,除了在II族中观察到的4级血液学毒性之外,在任一组中没有观察到急性4或5个不良事件。在一个月的手术中,关于≥3级术后并发症没有显着差异(p = 0.333)。结论对于肛门边缘至少5厘米的直肠癌患者,短路放疗与同时和固结化疗和延迟手术在急性毒性,术后发病性,完全切除和病理反应方面没有不同 - 与长期相比课程化学疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号